NOV 02, 2016 10:30 AM PDT

Vitamin D, Health Disparities in Prostrate Cancer, and...Alzheimer's

Speaker
  • Professor of Radiation Oncology - Medical University of South Carolina, Health Research Scientist & Research Integrity Officer, Ralph H. Johnson VA Medical Center
    Biography
      Dr. Sebastiano Gattoni-Celli received his MD from the University of Naples Medical School before completing his Residency in Oncology at Catholic University Medical School in Rome and a Fellowship in Molecular Biology at New York University Medical Center. He is currently a Professor of Radiation Oncology at the Medical University of South Carolina and a Health Research Scientist at the Ralph H Johnson VA Medical Center in Charleston, SC.

      For the past decade, vitamin D3 supplementation studies have been an important aspect of his research efforts. Specifically, he has explored the impact that hypovitaminosis D can have on the health of very large segments of the population. Dr. Gattoni-Celli is currently examining the possibility that long-term vitamin D deficiency may contribute to the progression from subclinical prostate cancer to clinical disease, especially among African American men. Dr. Gattoni-Celli is actively conducting clinical trials to determine whether vitamin D3 supplementation in patients diagnosed with early-stage, low-risk prostate cancer will yield improved therapeutic clinical and survival outcomes.

    Abstract

    Vitamin D3 supplementation can effectively remedy the current epidemic of vitamin D deficiency, especially within the African-American population and the elderly of any ethnicity. Racial disparities in prostate cancer outcomes mirror racial differences in vitamin D levels, as African American men exhibit a high prevalence of hypovitaminosis D, raising the possibility that long-term vitamin D deficiency may contribute to the progression from subclinical prostate cancer to clinical disease, especially among African American men. Therefore, eliminating racial disparities in circulating levels of vitamin D could have important implications for reducing disparities in prostate cancer outcomes. The efficacy of this approach has been clearly demonstrated during the course of clinical trials (conducted as a PI under FDA IND 77,839), employing robust vitamin D3 supplementation in patients diagnosed with early-stage, low-risk prostate cancer. Dr. Gattoni-Celli and others recently reported that daily supplementation with 4000 IU of vitamin D3 for one year is safe and is associated with a decrease in the number of positive cores at repeat biopsy; this regimen “erases” any vitamin D deficiency or insufficiency in all the patients enrolled in the study. Furthermore, research has shown that supplementation eliminates racial disparities in serum levels of 25(OH)D between African American and white men. Additionally, separate preclinical studies have demonstrated that a vitamin D-rich diet in an animal model of Alzheimer’s disease results in a significant decrease in the size and number of amyloid plaques in the brain of supplemented mice, compared to controls.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    Loading Comments...
    Show Resources
    Attendees
    • See more